99 recruiting. 99 Phase 2, 19 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 99 | Recruiting 99 |
| Phase 1 | 19 | Recruiting 19 |
| Phase 3 | 4 | Recruiting 4 |
Follow Sample Collection: new trials by email Literature Review of Sample Collection trials Research Report on Sample Collection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced Pancreatic Ductal Adenocarcinoma Biospecimen Collection, Diagnostic Imaging Testing, Echocardiography Test - Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 31 | 2027-06-01 | 2026-10-22 |
| Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial Balstilimab, Biopsy Procedure, Biospecimen Collection - Colorectal Adenocarcinoma, Stage II Colorectal Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 20 | 2027-05-25 | 2026-09-29 |
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-11-04 |
| Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial Balstilimab, Biospecimen Collection, Botensilimab - Clear Cell Renal Cell Carcinoma, Stage II Renal Cell Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2027-05-17 | 2026-10-21 |
| A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information Biospecimen Collection, Chest Radiography, Computed Tomography - Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8 | Phase 2 | Recruiting | Children's Oncology Group | 51 | 2027-05-15 | 2026-09-24 |
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-26 |
| Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2027-04-12 | 2026-10-16 |
| Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene Biopsy Procedure, Biospecimen Collection, Computed Tomography - Burkitt Lymphoma, Double-Expressor Lymphoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 50 | 2027-01-11 | 2026-10-14 |
| Hotspot Stereotactic Ablative Radiotherapy Versus Traditional Stereotactic Ablative Radiotherapy for the Treatment of Early-Stage Non-Small Cell Lung Cancer Biospecimen Collection, Computed Tomography, Lymph Node Biopsy - Early Stage Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8 | Phase 2 | Recruiting | Roswell Park Cancer Institute | 200 | 2026-12-01 | 2026-11-05 |
| Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial Lutetium Lu 177 Vipivotide Tetraxetan, Cell-free Circulating Tumor DNA Assay, Computed Tomography - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | University of Washington | 64 | 2026-11-15 | 2026-10-19 |
| Proton Spatially Fractionated Radiotherapy or Photon Stereotactic Body Radiotherapy in Combination With Pembrolizumab Before Surgery for the Treatment of Locally Advanced and Radiation-Naive Locoregionally Recurrent Oral Cavity Cancer, OSPRI Trial Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Recurrent Oral Cavity Squamous Cell Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 30 | 2026-11-04 | 2026-11-06 |
| Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell Therapy Axicabtagene Ciloleucel, Biospecimen Collection, Brexucabtagene Autoleucel - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma | Phase 2 | Recruiting | University of Michigan Rogel Cancer Center | 26 | 2026-11-01 | 2026-10-23 |
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial Biospecimen Collection, Computed Tomography, Electronic Health Record Review - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma | Phase 2 | Recruiting | Northwestern University | 125 | 2026-10-26 | 2026-10-29 |
| Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer Quemliclustat, Biospecimen Collection, Computed Tomography - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 27 | 2026-10-20 | 2026-10-22 |
| Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma Rituximab, Tafasitamab, Biospecimen Collection - Classic Follicular Lymphoma, Grade 1 Follicular Lymphoma | Phase 2 | Recruiting | University of Washington | 30 | 2026-10-09 | 2026-10-15 |
| DCE-MRI for Neoadjuvant Treatment Assessment in Patients With Borderline Resectable Pancreatic Cancer Biospecimen Collection, Computed Tomography, Dynamic Contrast-Enhanced Magnetic Resonance Imaging - Borderline Resectable Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 50 | 2026-10-01 | 2026-10-05 |
| Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Cytarabine - Core Binding Factor Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 162 | 2026-09-28 | 2026-11-04 |
| Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Biospecimen Collection, Bone Marrow Aspiration, Decitabine and Cedazuridine - Acute Myeloid Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 126 | 2026-09-25 | 2026-11-06 |
| Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy Anti-VEGF Monoclonal Antibody, Bevacizumab, Biospecimen Collection - Recurrent Platinum-Sensitive Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Platinum-Sensitive Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 87 | 2026-09-24 | 2026-11-09 |
Showing 20 of 99. Sign in to see all of them.
Leukemia, Myeloid, Acute (8) · Burkitt Lymphoma (5) · Neoplasm Metastasis (5) · Prostatic Neoplasms (5) · Carcinoma, Renal Cell (4) · Colorectal Neoplasms (4) · Urinary Bladder Neoplasms (4) · Adenocarcinoma Of Esophagus (3) · Breast Carcinoma In Situ (3) · Breast Neoplasms (3) · Carcinoma (3) · Carcinoma, Intraductal, Noninfiltrating (3) · Laryngeal Neoplasms (3) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lung Neoplasms (3)
National Cancer Institute (NCI) (75) · Children's Oncology Group (3) · Mayo Clinic (3) · University of Washington (3) · Fred Hutchinson Cancer Center (2) · NRG Oncology (2) · Northwestern University (2) · Ohio State University Comprehensive Cancer Center (2) · ECOG-ACRIN Cancer Research Group (1) · Jennifer Woyach (1) · Kerry Rogers (1) · Naresh Bumma (1) · PedAL BCU, LLC (1) · Roswell Park Cancer Institute (1) · University of Michigan Rogel Cancer Center (1)
United States (99) · Puerto Rico (18) · Canada (16) · Australia (9) · New Zealand (3) · Hong Kong (1) · Ireland (1) · Israel (1) · Singapore (1)
A P Chen (2) · Anand A Patel (2) · Anwaar Saeed (2) · Haider S Mahdi (2) · Rosa Nadal Rios, MD, PhD (2) · Aaron S Mansfield (1) · Adanma Anji Ayanambakkam Attanathi (1) · Ajay Bansal, MD (1) · Alan L Ho (1) · Andrea B Apolo (1) · Andreas N Saltos (1) · Bhavana Konda (1) · Brett L Ecker, MD (1) · Brian C Baumann (1)
PMID 35622074, PMID 41671463, PMID 35031545, PMID 36902217, PMID 37222189, PMID 37673112, PMID 38501690, PMID 40155326, PMID 41026957, PMID 41213241, PMID 42131734, PMID 42949119
U10CA180888 (10), U10CA180821 (9), U10CA180820 (8), U10CA180868 (8), U10CA180886 (8), UM1CA186691 (7), UG1CA242632 (5), P30CA046592 (4), P30CA060553 (4), UM1CA186689 (4), UG1CA242596 (3), UM1CA186688 (3), U10CA180863 (2), UG1CA189828 (2), UG1CA242635 (2)